Sas TC, Comme-Dijkhuis AH, de Muinck Keizer Schrama SM, et al. 1999b. The effects of long-term growth hormone treatment on cardiac left ven- tricular dimensions and blood pressure in girls with Turner’s syndrome. Dutch Working Group on Growth Hormone. J Pediatr, 135:470–46. Siegel PT, Clopper R, Stabler B. 1998. The psychological consequences of Turner syndrome and review of the National Cooperative Growth Study psychological substudy. Pediatr, 102:488–91. Soriano-Guillen L, Coste J, Ecosse E, et al. 2005. Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone. J Clin Endocrinol Metab, 90:5197–204. Suganuma N, Furuhashi M, Hirooka T, et al. 2003. Bone mineral density in adult patients with Turner’s syndrome: Analyses of the effectivemess of GH and ovarian steroid hormonal replacement therapies. Endocr J, 50:263–9. Vab deb Berg J, Bannink EM, Wielopolski PA, et al. 2006. Aortic disten- sibility and dimensions and the effects of growth hormone treatment in the Turner Syndrome. The Amer J Card, 97:1644–9. Van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, et al. 2003. Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens, J Clin. Endocrinol Metab, 88:1119–25. Van Teunenbrock A, Muinck Keizer-Schrama de SMPF, Aanstoot HJ, et al. 1999. Carbohydrate and lipid metabolism during various growth hormone dosing regimens in girls with Turner syndrome. Metab, 48:7–14. GH and Turner syndrome Welse M, James D, Leitner CH, et al. 1993. Glucose metabolism in Ullrich-Turner syndrome: long-term effects of therapy with human growth hormone. Horm Res, 39:39–41. Wilson DM, Rosenfeld RG, Genentech Turner Collaborative Group. 1991. Effect of GH and oxandrolone on carbohydrate and lipid metabolism. In: Ranke MB, Rosenfeld RG (eds). Turner syndrome: growth promoting therapies. Amsterdam: Elsevier Science Publishers BV. p. 269–74. Zadik Z, Landau H, Chen M, et al. 1992. Assessment of growth hormone (GH) axis in Turner’s syndrome using 24-hour integrated concentrations of GH, insulin-like growth factor-I, plasma GH-binding activity, GH binding to IM9 cells and GH response to pharmacological stimulation. J Clin Endocrinol Metab, 75:412–6. Zinn AR, Ross JL: Critical regions for Turner syndrome phenotypes on the X chromosome. 2000. In: Saenger P, Pasquino AM (eds). Optimiz- ing Health Care for Turner Patients in the 21st century. Amsterdam, Elsevier. p. 19–28. Zinn AR, Roeltgen D, Stafanatos G, Ramos P, Elder FF, Kushner H, Kowal K, Foss JL. 2007. A Turner syndrome neurocognitive phenotype maps to X p. 22.3. Behav Brain Funct, 3:24. Therapeutics and Clinical Risk Management 2008:4(6) 1183